Scancell Share Discussion Threads

[inanaco] 07/2/2024 09:08

well we will soon know in March

[marcusl2] 07/2/2024 09:02

I think it is actually at 16m20s

[marcusl2] 07/2/2024 08:57

Cleanerworld

Prof Sarah Danson author on the Scope trial poster and lead investigatoron modi trial in Sheffield , speaker at melanoma conference 2024Today 08:48
Melanoma Patient Conference 2024

Thursday 29th February – Friday 1st March, 2024

Location: Voco St Johns Hotel, Solihull, Birmingham, B91 1AT



09:25am - 10:55am SESSION ONE: Updates in Melanoma Medicine

Chair: Imogen Cheese

09:25am - 09:55am Clinical Trials Update. Innovation and Progress (Professor Sarah Danson)

The clinical trails update is important and will be interesting, because

Prof Sarah Danson , was listed as an author on the poster presented in November 2023 SCOPE trial to be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer



Poster presentation title A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab

+ ipilimumab in patients with advanced unresectable melanoma: Efficacy and

safety results from the open-label Phase 2 SCOPE trial

Authors Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson,

Martin Highley, Clare Barlow, Robert Miller, Fayaz Master and Lindy Durrant

Abstract number 1533

Session date and time Friday, Nov. 3, 2023, 9am – 7pm EDT

Location Exhibit Halls A and B1 – San Diego Convention Center

Also listed as investigator at the Modify tirial

Principal Investigator Prof Sarah Danson at

Cancer Clinical Trials Centre
Weston Park Cancer Centre
Whitham Road
Sheffield
S10 2SJ



Previously in 2022 you tube link from Sarah Danson



21 mins in Scope trial explained

[torquayfan] 06/2/2024 23:48

Hi Inan. Good to see all those posts and your undiminished conviction about Scancell! An interesting discussion on the LF thread too. ATB

[marcusl2] 06/2/2024 21:53

Novartis paying €2.7B for longtime antibody player Morphosys

[chilltime] 06/2/2024 19:29

Welcome 3nobody

Good to have someone on board that knows Ultimovacs well.

It’s good to have 2 companies attacking from the same angle as it helps remove doubt of a flash in the pan result.

In general over time it seems there was a view that peptide/DNA vaccines don’t work.

Mrna and personalised vaccines being the only way to go.

So for two in quick time to drop in good results would be fantastic.

I did read about one peptide type vaccine that achieved very little and went no further.



It’s not that peptide vaccines don’t work, those involved just didn’t have the tight answer.

So companies like Ultimovacs and Scancell have been sat in dark room ignored by the masses. Over the next few months both should be well under the spotlight of big pharma companies.

Obviously BMS have a head start as they are with both, which is down to the CPI combo being the standard of care.

Ulti have done Scancell a favour as 78 of those are just the CPI combo. Fresh data to compare against.

[marcusl2] 06/2/2024 15:29

Explained better at the AGM
From around 45m

[3nobody] 06/2/2024 14:37

marcus,

I have listened through the 30 Jan. presentation by Lindy. The Audio is a little bad and I have not found the part where Lindy think their vaccine is inferior to Ultimovacs. Could you possible narrow down where in the presentation this is discussed?

[inanaco] 06/2/2024 14:28

and a quote and deal

[inanaco] 06/2/2024 14:28

with Barclays

[nigelpm] 06/2/2024 14:27

None - I did a dummy purchase of 50k - quoted 11.78.

Consider another broker if you aren't getting quotes that often.

[inanaco] 06/2/2024 14:14

so how many did u buy

[supernumerary] 06/2/2024 14:07

Sci - thanks - I know you can trade pretty much anything on the derivatives platforms, but at the time I was looking at a multi-year hold, so I didn't think that CFD/SBs were really suitable.

[nigelpm] 06/2/2024 14:04

Plenty available just not below offer price.

[inanaco] 06/2/2024 13:58

had to do two £500 trades

[inanaco] 06/2/2024 13:38

still cant

[marcusl2] 06/2/2024 13:06

It is interesting that Ultimovacs and Scancell are both using Bristol Myers Squibb
ipilimumab and nivolumab.

Ulti in Melanoma and Meso

Scancell in Melanoma and RCC

BMS may be interested!

ipilimumab /Yervoy® patents will expire in the US in 2023 and expired in the EU in 2021.
nivolumab /Opdivo's patent will expire in 2028


Scancell also has Avidimab which could extend patent life.

[3nobody] 06/2/2024 12:48

marcus,

Thanx. Interesting thought from Lindy. I shall listen closely to latest presentation.

[sci102] 06/2/2024 12:42

Super, you can trade it with IG but only on their CFD platform which is not worth it for longer term holds.

[supernumerary] 06/2/2024 12:31

3n - thanks, I guessed that was the case. I seem to remember that some sort of cross-listing was later arranged on a European exchange, but I couldn't find that either. I think the opportunity I saw then has now passed - it's appreciated quite a lot recently - so it's no longer on my hit list. Still a very interesting company and drug. Good luck with it!

[3nobody] 06/2/2024 12:25

supernumerary,

Since I am Norwegian citizen I trade Ultimovacs through norwegian stock exchange (OSE:OSLO). Unfortunately, to my knowledge, Ultimovacs is not tradeable on other exchanges.

But I understand your problem as I face the same problem trading Scancell.
Personal I use Saxo Bank when trading stocks outside Norway, since you can have multiple currency accounts and dont need to exchange currency for each transaction.

[marcusl2] 06/2/2024 12:22

I listened to Lindy again.

At this point in this space Ultimovacs is our only competitor in Melanoma and they are using doublet like us.

She thinks their vaccine is inferior as it only targets a single antigen.

That is why we have not moved forward with Scib-2 as it only targets a single antigen (NY-ESO-1) and she thinks there would be an immune escape.

She also thinks if scib/iScib+ works we will beat Moderna hands down as we are off the shelf.

Moderna has told her "if you are correct Lindy then we are in trouble"


SCIB1 incorporates specific epitopes from the proteins gp100 and TRP-2, which were identified from the cloning of T cells from patients who achieved spontaneous recovery from melanoma skin cancers. Both proteins play key roles in the production of melanin in the skin.

[inanaco] 06/2/2024 12:18

you may think what am i talking about here

unintended consequence

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1

or how it stacks up against SCIb1 and moditope

if its the cytotoxic CD4 (moditope) kick starting the UV1 vaccine with ctla-4.... which it appears to be as this vaccine has by chance induced some cd4 helper going cytotoxic an untended consequence it just highlights still how potent they are as they appear in the responders

so its a plus for Moditope ... further proof that CD4 Killer t cells are of significant value


with SCIB1 in direct competition


another spin off from Lindy presentation ......... the New patent


well here is UV1

[inanaco] 06/2/2024 12:05

This confirmed both the coreceptor independency of Radium-4 TCR and the cytolytic capacity of both CD8 and CD4 T cell subsets. Taken together, these data support that melanoma cells expressing a modified Ii chain construct, ESTDAB-1000, could be used as a model target for CD4 TCR-dependent T cell cytotoxicity.